Preliminary Outcomes of Orelabrutinib Plus R-CHOP in Treatment-Naive Patients with Double-Expression Diffuse Large B-Cell Lymphoma

布鲁顿酪氨酸激酶 弥漫性大B细胞淋巴瘤 切碎 癌症研究 淋巴瘤 医学 美罗华 伊布替尼 内科学 肿瘤科 免疫学 酪氨酸激酶 白血病 慢性淋巴细胞白血病 受体
作者
Yang Yang,Jingsong He,Yi Zhao,Wenjun Wu,Gaofeng Zheng,Xiaoyan Han,Donghua He,Tao Cheng,Zhen Cai
出处
期刊:Blood [American Society of Hematology]
卷期号:142 (Supplement 1): 6222-6222
标识
DOI:10.1182/blood-2023-187906
摘要

Background Double-expression lymphoma (DEL), a type of diffuse large B cell lymphoma (DLBCL) with co-expression of MYC and BCL2 proteins without gene rearrangements, is associated with poor prognosis for patients. The double expression of MYC and BCL2 may result in the activation of the B cell receptor (BCR) signaling pathway. Bruton tyrosine kinase (BTK) serves as a rational therapeutic target for DEL due to its crucial role in BCR signaling. The Phoenix study demonstrated that ibrutinib (first generation of BTK inhibitor) plus R-CHOP could improve event-free survival (EFS) and overall survival (OS) in younger patients with DEL. Orelabrutinib is a novel BTK inhibitor with high selectivity to BTK. Orelabrutinib has been shown in a preclinical study that it could preserve the NK-cell-mediated antibody-dependent cellular cytotoxicity induced by rituximab, and combination with R-CHOP (O-RCHOP) displayed higher anti-tumor activity than either alone in vivo or in vitro. This study aimed to evaluate the efficacy and safety of the O-RCHOP regimen in the treatment of naive patients with DEL DLBCL. Methods This was a prospective, single-arm, phase II study recruiting treatment-naive patients with DEL DLBCL. DEL was defined as≥40% positive rate for MYC and ≥50% for BCL2 by immunohistochemistry. The double-hit cases (with gene rearrangement) were excluded. All patients were treated for 6-8 cycles with 21 days per cycle. They received 150 mg of orelabrutinib once daily on days 1-14 combined with R-CHOP (Rituximab 375 mg/m 2, cyclophosphamide 750 mg/m 2, liposome doxorubicin 30 mg/m 2, vincristine 1.4 mg on day 1, and prednisone 100 mg daily on days 1-5). The primary endpoint was EFS. The response was assessed after 4 or 6 cycles using PET-CT. Adverse events (AEs) were assessed according to the Common Terminology Criteria for Adverse Events v 5.0. Results From March 27, 2021 to June 7, 2023, 15 patients with DEL were enrolled. All patients received an O-RCHOP regimen and 13 patients . The baseline characteristics of the patients were listed in Table 1. Thirteen patients who had received at least 4 cycles of treatment achieved CR (100.0%; Figure 1). After a median follow-up of 14.6 months (1.5-27.1 months), the estimated 12-month EFS rate was 100.0%. None of the 13 patients experienced disease progression or death at the cutoff date. Three of the 15 patients had the mutation of TP53 with or without other cytogenetic abnormalities tested by NGS. Grade 3/4 AEs were mainly hematological toxicity including febrile neutropenia (20%; 3/15), neutropenia (66.7%; 10/15), anemia (13.3%; 2/15), and thrombocytopenia (6.6%; 1/15), which were manageable. Neutropenia mainly occurred after the first cycle of chemotherapy, which improved after prophylaxis of PEG-rhG-CSF. The incidence of all-cause infection was 13.3% (2/15) . No atrial fibrillation, tumor lysis syndrome, or hemorrhage were observed. No patients discontinued treatment due to toxicity. Conclusion The combination of orelabrutinib and RCHOP showed encouraging efficacy and a tolerable safety profile in DEL DLBCL in this preliminary analysis. More updated data from this ongoing study will be provided in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王爷教你白给完成签到 ,获得积分10
1秒前
有魅力荟完成签到,获得积分10
2秒前
Sober完成签到 ,获得积分10
4秒前
5秒前
扒开皮皮完成签到,获得积分20
6秒前
称心的海蓝完成签到 ,获得积分10
7秒前
黄花菜完成签到 ,获得积分10
9秒前
光亮秋天完成签到 ,获得积分10
13秒前
14秒前
自由的无色完成签到 ,获得积分10
15秒前
云上人完成签到 ,获得积分10
15秒前
Luna完成签到 ,获得积分10
17秒前
诗筠完成签到 ,获得积分10
18秒前
Jasper应助扒开皮皮采纳,获得10
21秒前
后陡门的夏天完成签到 ,获得积分10
21秒前
talksilence完成签到,获得积分10
26秒前
125完成签到,获得积分10
26秒前
大脸猫完成签到 ,获得积分10
28秒前
29秒前
luojie完成签到 ,获得积分10
32秒前
32秒前
yszyy23完成签到 ,获得积分10
35秒前
扒开皮皮发布了新的文献求助10
35秒前
清新的音响完成签到 ,获得积分10
36秒前
hj0806完成签到,获得积分0
38秒前
小不完成签到 ,获得积分10
39秒前
39秒前
多情以山完成签到 ,获得积分10
45秒前
45秒前
复杂念梦完成签到 ,获得积分10
48秒前
davyean完成签到,获得积分10
49秒前
牛奶面包完成签到 ,获得积分10
51秒前
456完成签到,获得积分10
1分钟前
我和你完成签到 ,获得积分10
1分钟前
z1005完成签到 ,获得积分20
1分钟前
April完成签到 ,获得积分10
1分钟前
畅快枕头完成签到 ,获得积分10
1分钟前
1分钟前
iShine完成签到 ,获得积分10
1分钟前
快乐的小木虫完成签到,获得积分10
1分钟前
高分求助中
Exploring Mitochondrial Autophagy Dysregulation in Osteosarcoma: Its Implications for Prognosis and Targeted Therapy 4000
Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms 2000
Evolution 1100
How to Create Beauty: De Lairesse on the Theory and Practice of Making Art 1000
Research Methods for Sports Studies 1000
Gerard de Lairesse : an artist between stage and studio 670
Assessment of Ultrasonographic Measurement of Inferior Vena Cava Collapsibility Index in The Prediction of Hypotension Associated with Tourniquet Release in Total Knee Replacement Surgeries under Spinal Anesthesia 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 内科学 物理 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 免疫学 病理 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 2980312
求助须知:如何正确求助?哪些是违规求助? 2641388
关于积分的说明 7124950
捐赠科研通 2274335
什么是DOI,文献DOI怎么找? 1206476
版权声明 592018
科研通“疑难数据库(出版商)”最低求助积分说明 589477